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ABSTRACT 
Elevated level of LDL is the most important risk factor for atherosclerosis. ApoB100 is the 
only unexchangeable protein in LDL particle. Recent reports have shown that native peptides 
of ApoB100 trigger activation of adaptive immune responses. Whether ApoB100 can activate 
innate immune response is less-known. 
In this thesis, we identified a native ApoB100 peptide from human ApoB100, named 
ApoB100 danger associated signal-1 (ApoBDS-1), given its biological nature to trigger 
innate proinflammatory responses in monocytes and macrophages. Besides macrophages, 
ApoBDS-1 can also activate platelets and endothelial cells, eliciting proinflammatory 
mediators and promoting platelet-leukocyte aggregates through complex molecular 
mechanisms involving Ca2+ flux, ROS production, MAPKs activation, PI3K-Akt activation, 
and microRNA regulations. ApoBDS-1 contributes to the activation of inflammatory 
signaling in human atherosclerotic plaque. We showed that ApoBDS-1 exists in human 
carotid plaques by immunofluorescence staining. Size-exclusion chromatography and 
Western blot confirmed that some low molecular weight fractions isolated from plaque 
contain ApoBDS-1 epitopes and possess ApoBDS-1-like bioactivity for induction of IL-8. 
These findings suggest that active ApoBDS-1 presents in atherosclerotic lesions. Analysis of 
BiKE database indicates that inflammasome pathways are involved in atherosclerosis and 
associated with the disease severity. Our studies show that ApoBDS-1 is an endogenous 
activator of NLRP3 inflammasome, inducing IL-1β in monocytes and macrophages via 
NLRP3-dependent caspase-1 activation. We also found that ApoBDS-1 could induce NLRP3 
inflammasome complex formation in vivo, and activate NLRP3 inflammasome by induction 
of K+ efflux. Lastly, we explored the receptor/interacting protein for ApoBDS-1 using far 
Western blot and 2-D electrophoresis and identified TNF receptor associated protein 1 
(Trap1) as an ApoBDS-1 specific interacting protein. Trap1 and ApoBDS-1 are colocalized 
mainly in cytoplasm and also on cell surface membrane. Biacore SPR analysis suggests that 
ApoBDS-1 binds to Trap1 with a medium affinity depending on the last 5 amino acids in its 
C-terminal domain. Trap1 is indispensable for ApoBDS-1 function since ApoBDS-1 induced 
cytokine secretion and reactive oxygen species can be inhibited by Geldanamycin, an 
inhibitor of Trap1 or by knocking down of Trap1 using specific shRNA.   
Taken together, we have identified ApoBDS-1 as the innate immune activator in ApoB100. 
Blocking the interaction of ApoBDS-1 and Trap1, or inhibition of ApoBDS-1 induced 
signaling pathways may represent new therapeutic options for atherosclerosis treatment.                   
